-
Who we are
Who we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
What we do
What we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Investor Hub
Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.
Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Latest publications
Annual report
NASDAQ:NVAX
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Stock details
Historical stock price
Analyst coverage
Mayank Mamtani
B. Riley FBR
Alec Stranahan, PhD
BofA Securities
Brendan Smith, PhD
TD Cowen
Vernon Bernardino
H.C. Wainwright & Co.
Roger Song, MD, CFA
Jefferies
Eric Joseph, PhD
JP Morgan
The analysts listed on this page follow Novavax. Please note that any opinions, estimates or forecasts regarding Novavax' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novavax or its management. Novavax does not by its reference above or distribution imply its endorsements of or concurrence with such information, conclusions or recommendations.
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.
Investor inquiries
Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.